HOUSTON, Nov. 1 /PRNewswire-FirstCall/ -- Encysive Pharmaceuticals today announced the appointment of Gordon H. Busenbark as Chief Financial Officer, a new position in the Company. Mr. Busenbark brings more than two decades of global financial and healthcare industry experience to Encysive as the Company prepares for the potential 2006 North American and European launch of its lead product candidate, Thelin(TM) (sitaxsentan sodium).
Mr. Busenbark joins Encysive from Baxter Healthcare Corporation, an Illinois-based, $9.0 billion global healthcare company, where he served for over 23 years in various management positions, including Divisional Chief Financial Officer and Division President.
“Gordon is a seasoned leader in the international pharmaceutical industry, with strengths in global financial management and international operations,” stated Bruce D. Given, M.D., President and Chief Executive Officer of Encysive. “His experience will be integral in guiding Encysive’s evolution into a profitable biopharmaceutical company with operations in North America and Europe.” In addition to his responsibilities as CFO, Mr. Busenbark will be charged with overseeing business development and information technology for the Company.
Previously, Mr. Busenbark served as President of Plasma Therapeutics for Baxter’s Bioscience Division in Vienna, Austria. He managed profit and loss and operations, and directed the division’s Global Operations organization, including nine manufacturing facilities in the United States and Europe, and global supply chain and information systems organizations. During his role as CFO, he managed all financial functions of the division, including financial integration of Baxter’s acquisition of Immuno AG. Mr. Busenbark holds an M.B.A. and a Bachelor’s degree from the University of Utah.
About Encysive Pharmaceuticals
Encysive Pharmaceuticals Inc. is a biopharmaceutical company engaged in the discovery, development and commercialization of novel, synthetic, small molecule compounds to address unmet medical needs. Our research and development programs are predominantly focused on the treatment and prevention of interrelated diseases of the vascular endothelium and exploit our expertise in the area of the intravascular inflammatory process, referred to as the inflammatory cascade, and vascular diseases. We have successfully developed one FDA-approved drug, Argatroban, for the treatment of heparin-induced thrombocytopenia that is marketed by GlaxoSmithKline. The NDA for our lead drug candidate Thelin(TM) (sitaxsentan sodium), an endothelin A receptor antagonist for the treatment of PAH, is now under active review by the Cardio- Renal Division of the FDA. The European Agency for the Evaluation of Medicinal Products is currently reviewing a Marketing Authorization Application for approval of Thelin within the European Union. In addition, we have an earlier stage clinical product candidate in development, TBC3711, a next generation endothelin receptor antagonist. To learn more about Encysive Pharmaceuticals please visit our web site: http://www.encysive.com .
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements are subject to certain risks, trends and uncertainties that could cause actual results to differ materially from those projected. Among those risks, trends and uncertainties are our estimate of the sufficiency of our existing capital resources, our ability to raise additional capital to fund cash requirements for future operations, timelines for initiating new clinical trials, planned announcements of clinical data, the possibility of obtaining regulatory approval, our ability to manufacture and sell any products, potential drug candidates, their potential therapeutic effect, market acceptance or our ability to earn a profit from sales or licenses of any drug candidate, our ability to discover new drugs in the future, and our ability to establish future collaborative arrangements. In particular, careful consideration should be given to cautionary statements made in the various reports Encysive, including as Texas Biotechnology Corporation, has filed with the Securities and Exchange Commission. Encysive undertakes no duty to update or revise these forward-looking statements.
Encysive Pharmaceuticals Inc.
CONTACT: investors, Ann Tanabe of Encysive Pharmaceuticals Inc.,+1-713-796-8822; or Marcy Strickler of The Trout Group, +1-212-477-9007,ext. 27; or media, Dan Budwick of BMC Communications, +1-212-477-9007, ext.14, both for Encysive Pharmaceuticals Inc.
Web site: http://www.encysive.com/
